Search results
Results from the WOW.Com Content Network
Bupivacaine, marketed under the brand name Marcaine among others, is a medication used to decrease sensation in a specific small area. [5] In nerve blocks , it is injected around a nerve that supplies the area, or into the spinal canal's epidural space . [ 5 ]
In the European Union, the combination bupivacaine/meloxicam is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. [ 2 ] In the United States it is indicated for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open ...
The American Society of Health-System Pharmacists (ASHP) reported that 323 "active medication shortages" were reported in January–March 2024. As a result of drug scarcity, many healthcare systems were forced to either ration out essential drugs, triage patients based on the severity of their condition and their need for the drug, or both.
bupivacaine: Marcaine, Sensorcaine, Vivacaine 1957 (Ekenstam) 1963 (Widman and Telivuo) Amide Moderate butacaine: ester- aminobenzoic butanilicaine: Amide chloroprocaine: Nesacaine Ester - Aminobenzoic cinchocaine (INN) dibucaine (USAN), Cincain, Cinchocaine, Nupercainal, Nupercaine, Sovcaine 1925 (Meischer) 1930 (Uhlmann) Ester - Aminobenzoic ...
Get answers to your AOL Mail, login, Desktop Gold, AOL app, password and subscription questions. Find the support options to contact customer care by email, chat, or phone number.
Find us on X (formerly known as Twitter) or Facebook. Paid members In addition to the support options listed above, paid members also have access to 24/7 phone support by calling 1-800-827-6364.
[1] [2] Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine and has a longer motor block onset time. [3] Ropivacaine is, next to levobupivacaine, another less cardiotoxic alternative to bupivacaine. [4]
The United States Patent and Trademark Office (USTPO) issued Tonix Pharmaceuticals U.S. Patent No. 11, 345, 896, entitled “Synthetic Chimeric Poxviruses” in May 2022. This patent applies to synthetic horsepox virus, the basis for the Company's TNX-801 vaccine and Recombinant Pox Virus (PRV) platform, and is anticipated to grant Tonix with U ...